• Robert R. Jacobson


Leprosy (Hansen’s disease) is a chronic infectious disease caused by Mycobacterium lepraethat primarily affects the skin, peripheral nerves, eyes, and mucous membranes. It has been known for well over 2000 years and afflicts more than 11 million people worldwide, mostly in underdeveloped nations. Hansen(31) discovered the etiological agent over 100 years ago, but it has still not definitely been cultured in artificial media, and there is much about the disease process we do not understand. In particular, relatively few good studies on the epidemiology and control of leprosy have been done.


Household Contact Leprosy Patient Lepromatous Leprosy Mycobacterium Leprae Skin Scraping 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abe, M., Fluorescent leprosy antibody absorption (Fla-Abs) test for detecting subclinical infection with Mycobacterium leprae, Int. J. Lepr. 47:379 (1979) (abstract).Google Scholar
  2. 2.
    Amezcua, M. E. , Escobar-Gutiérrez, A., Mayen, E., and Cazares, J. V., Sensitivity and specificity of the FLA-ABS test for leprosy in Mexican populations, Int. J. Lepr. 55:277– 285 (1987).Google Scholar
  3. 3.
    Badger, L. F. , Leprosy in the United States, Public Health Rep. 70:525–535 (1955).PubMedGoogle Scholar
  4. 4.
    Badger, L. F. , Epidemiology, in: Leprosy in Theory and Practice, 2nd ed. (R. G. Cochrane, and T. F. Davey, eds.), pp. 69–97, John Wright, Bristol, 1964.Google Scholar
  5. 5.
    Bahong, J., and Noordeen, S. K. , Leprosy, in: Tropical Disease Research: A Global Partnership (J.Maurice and A. M. Pearce, eds.), pp. 113–124, WHO, Geneva, 1987.Google Scholar
  6. 6.
    Bechelli, L. M. , Garbojosa, P. G., Gyi, M. M. , and Martinez-Dominguez, V. , Site of early skin lesions in children with leprosy, Bull. WHO 48:107–111 (1973).PubMedGoogle Scholar
  7. 7.
    Bechelli, L. M., Lwin, K., Garbajosa, P. G., Gyi, M. M., Uemura, K. , Sundaresan, T. , Tamondong, C., Matejka, M., Sansarricq, H., and Walter, J., BCG vaccination of children against leprosy: Nine-year findings of the controlled WHO trial in Burma, Bull. WHO 51:93–99 (1974).PubMedGoogle Scholar
  8. 8.
    Brown, J. A. K., Stone, M. M., and Southerland, J., Trial of BCG vaccination against leprosy in Uganda, Lepr. Rev. 40:3–7 (1969).PubMedGoogle Scholar
  9. 9.
    Browne, S. G., The history of leprosy, in: Leprosy(R. C. Hastings, ed.), pp. 1–14, Churchill Livingstone, Edinburgh, 1985.Google Scholar
  10. 10.
    Brubaker, M. L., Binford, C. H., and Trautman, J. R., Occurrence of leprosy in U.S. veterans after service in endemic areas abroad, Public Health Rep. 84:1051–1058 (1969).PubMedGoogle Scholar
  11. 11.
    Bullock, W. E., Studies of immune mechanisms in leprosy. I. Depression of delayed allergic responses to skin test antigens, N. Engl. J. Med. 278:298–304 (1968).Google Scholar
  12. 12.
    Chacko, C. J. G., Mohan, M., Jesudasan, K., Job, C. K., and Fritschi, E. P. , Primary leprosy involvement of nasal mucosa in apparently healthy household contacts of leprosy patients, Int. J. Lepr. 47:417 (1979) (abstract).Google Scholar
  13. 13.
    Chakravatti, M. R., and Vogel, F., A twin study on leprosy, Topics in Human Genetics, No. 1, Thieme, Stuttgart, 1973.Google Scholar
  14. 14.
    Clark-Curtiss, J. E. , Jacobs, W. R. , Docherty, M. A., Ritchie, L. A. , and Curtiss, R. , Molecular analysis of Dna and construction of genomic libraries of Mycobacterium leprae, J. Bacteriol. 161:1093–1102 (1985).PubMedGoogle Scholar
  15. 15.
    Closs, O., In vitrolymphocyte response to purified protein derivative, Bcg and Mycobacterium leprae ina population not exposed to leprosy, Infect. Immun. 11:1163–1169 (1975).PubMedGoogle Scholar
  16. 16.
    Convit, J., Aranzazu, N., Ulrich, M., Pinardi, M. E., Reyes, O., and Alvarado, J. , Immunotherapy with a mixture of Mycobacterium lepraeand Bcg in different forms of leprosy and in Mitsuda-negative contacts, Int. J. Lepr. 50:415–424 (1982).Google Scholar
  17. 17.
    Davey, T. F., and Rees, R. J. W., The nasal discharge in leprosy: Clinical and bacteriologic aspects, Lepr. Rev. 45:121–134 (1974).PubMedGoogle Scholar
  18. 18.
    Desikan, K. B., Viability of Mycobacterium lepraeoutside the human body, Lepr. Rev. 48:231–235 (1977).PubMedGoogle Scholar
  19. 19.
    Dharmendra and Chatterjee, B. R. , Prognostic value of the lepromin test in contacts of leprosy cases, Lepr. India 27:149–158 (1955).Google Scholar
  20. 20.
    Donham, K. J. , and Leininger, J. R. , Spontaneous leprosy-like disease in a chimpanzee, J. Infect. Dis. 136:132–136 (1977).PubMedGoogle Scholar
  21. 21.
    Drutz, D. J., Chen, T. S. N., and Lu, W. H., The continuous bacteremia of lepromatous leprosy, N. Engl. J. Med. 287:159–164 (1972).PubMedGoogle Scholar
  22. 22.
    Enna, C. D. , Jacobson, R. R. , Trautman, J. R. , and Sturdivant, M. , Leprosy in the United States, 1967–1976, Public Health Rep. 93:468–473 (1978).PubMedGoogle Scholar
  23. 23.
    Faget, G. P. , Pogge, R. C., Johansen, F. A. , Dinan, J. F. , Prejean, B. M. , and Eccles, C. G. , The promin treatment of leprosy: A progress report, Public Health Rep. 58:1729–1741 (1943).Google Scholar
  24. 24.
    Filice, G. A. , and Fraser, D. W. , Management of household contacts of leprosy patients, Ann. Intern. Med. 88:538–542 (1978).PubMedGoogle Scholar
  25. 25.
    Fisher, C. A. , and Barksdale, L. , Elimination of the acidfastness but not the gram positivity of leprosy bacilli after extraction with pyridine, J. Bacteriol. 106:707–708 (1971).PubMedGoogle Scholar
  26. 26.
    Godal, T. , and Negassi, K. , Subclinical infection in leprosy, Br. Med. J. 3:557–559 (1973).PubMedGoogle Scholar
  27. 27.
    Godal, T. , Lofgren, M. , and Negassi, K. , Immune response to Mycobacterium lepraeof healthy leprosy contacts, Int. J. Lepr. 40:243–250 (1972).Google Scholar
  28. 28.
    Gormus, B. J., Wolf, R. H., Baskin, G. B., Ohkawa, S. G., Walsh, P. J., Meyers, W. M., Binford, C. H., and Greer, W. E. , A second sooty mangabey monkey with naturally acquired leprosy: First reported possible monkey-tomonkey transmission, Int. J. Lepr. 56:61–65 (1988).Google Scholar
  29. 29.
    Gray, H. H. , and Dreisbach, J. A. , Leprosy among foreign missionaries in northern Nigeria, Int. J. Lepr. 29:279–290 (1961).PubMedGoogle Scholar
  30. 30.
    Guinto, R. S. , Epidemiology of leprosy: Current views, concepts and problems, in: A Window on Leprosy(B. R. Chatterjee, ed.), pp. 36–53, Statesman Commercial Press, Calcutta, 1978.Google Scholar
  31. 31.
    Hansen, G. H. A., Undersogelser angaende Spedalskhedens Arsager, Nor. Mag. Laegevidensk. 4:76–79 (1874).Google Scholar
  32. 32.
    Harboe, M., The immunology of leprosy, in: Leprosy(R. C. Hastings, ed.), pp. 53–87, Churchill Livingstone, Edinburgh, 1985.Google Scholar
  33. 33.
    Harboe, M., and Closs, O., A revival of interest in antibody studies in leprosy? Int. J. Lepr. 47:372 (1979) (abstract).Google Scholar
  34. 34.
    Hastings, R. C., Transfer factor as a probe of the immune deficit in lepromatous leprosy, Int. J. Lepr. 45:281–291 (1977).Google Scholar
  35. 35.
    Immunological problems in leprosy research (2), Bull. WHO 48:483–492 (1973).Google Scholar
  36. 36.
    Ingrens, L. M. , and Kazda, J., The epidemiological significance of the occurrence of M. leprae-likemicroorganisms in the environment, Int. J. Lepr. 52:719 (1984).Google Scholar
  37. 37.
    Job, C. K. , Chacko, C. J. G. , Taylor, P. M. , Daniel, M., and Jesudian, G., Evaluation of cell mediated immunity in the histopathologic spectrum of leprosy using lymphocyte transformation test, Int. J. Lepr. 44:256–266 (1976).Google Scholar
  38. 38.
    Job, C. K., Harris, E. B. , Allen, J. L. ,and Hastings, R. C. , A random survey of leprosy in wild nine-banded armadillos in Louisiana, Int. J. Lepr. 54:453–457 (1986).Google Scholar
  39. 39.
    Khandekar, P. S. , Munshi, A. , Sinha, S. , Sharma, G., Kapoor, A., Gaur, A. , and Talwar, G. P. , Construction of genomic libraries of mycobacterial origin: Identification of recombinants encoding mycobacterial-specific proteins, Int. J. Lepr. 54:416–422 (1986).Google Scholar
  40. 40.
    Kirchheimer, W. F., and Prabhakaran, K., Metabolic and biologic tests on mycobacteria once labeled as leprosy bacilli, Int. J. Lepr. 36:589 (1968).Google Scholar
  41. 41.
    Kirchheimer, W. F. , and Storrs, E. E. , Attempts to establish the armadillo (Dasypus novencintusLinn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo, Int. J. Lepr. 39:693–702 (1971).Google Scholar
  42. 42.
    Kluth, F. C., Leprosy in Texas: Risk of contracting the disease in the household, Tex. State J. Med. 52:758–789 (1956).Google Scholar
  43. 43.
    Krieg, R. E., and Meyers, W. M., Demonstration of Mycobacterium lepraein tissues from bacteriologically negative treated lepromatous leprosy patients, Int. J. Lepr. 47:367 (1979) (abstract).Google Scholar
  44. 44.
    Lechat, M. F., Bellut, C., and Mission, C. B., The use and limitations of epidemiometric models in leprosy, in: A Window on Leprosy(B. R. Chatterjee, ed.), pp. 64–70, Statesman Commercial Press, Calcutta, 1978.Google Scholar
  45. 45.
    Leiker, D. L., Epidemiological and immunological surveys in Netherlands New Guinea, Lepr. Rev. 31:241–259 (1960).Google Scholar
  46. 46.
    Leprosy-like disease in wild-caught armadillos, Morbid. Mortal. Weekly Rep. 25:18, 23 (1976).Google Scholar
  47. 47.
    Lim, S. E. , Kiszkiss, E. F. , Jacobson, R. R. , Choi, Y. S., and Good, R. A., Thymus-dependent lymphocytes of peripheral blood in leprosy patients, Infect. Immun. 9:394–399 (1974).PubMedGoogle Scholar
  48. 48.
    Lumpkin, L. R. , III, Cox, G. F. , and Wolf, J. E., Jr., Leprosy in five armadillo handlers, J. Am. Acad. Dermatol. 9:899–903 (1983).PubMedGoogle Scholar
  49. 49.
    Mathai, R. , Rao, P. S. S. , and Job, C. K. , Risks of treating leprosy in a general hospital, Int. J. Lepr. 47:322 (1979) (abstract).Google Scholar
  50. 50.
    Mehra, V., Mason, L. H., Fields, J. P., and Bloom, B. R. , Lepromin induced suppressor cells in patients with leprosy, J. Immunol. 123:1813–1817 (1979).PubMedGoogle Scholar
  51. 51.
    Menzel, S., Bjune, G., Kronvall, G., and Morrow, R. H. , Lymphocyte transformation test in healthy leprosy contacts: Influence of household exposure, Int. J. Lepr. 47:374 (1979) (abstract).Google Scholar
  52. 52.
    Meyers, W. M. , Kvernes, S. , and Binford, C. H. , Comparison of reactions to human and armadillo lepromins in leprosy, Int. J. Lepr. 43:218–225 (1975).Google Scholar
  53. 53.
    Mohamed Ali, P. , and Ramanujam, K., Leprosy in twins, Int. J. Lepr. 34:405–407 (1966).Google Scholar
  54. 54.
    Narayanan, E. , Sreevatsa Kirchheimer, W. F., and Bedi, B. M. S., Transfer of leprosy bacilli from patients to mouse footpads by Aedes aegypti, Lepr. India 49:181–186 (1977).PubMedGoogle Scholar
  55. 55.
    Nathan, C. F., Kaplan, G., Levis, W. R., Nusrat, A., Witmer, M. D., Sherwin, S. A., Job, C. K., Horowitz, C. R. , Steinman, R. M. , and Cohn, Z. A. , Local and systemic effects of intradernal recombinant interferon-γ in patients with lepromatous leprosy, N. Engl. J. Med. 315:6–15 (1986).PubMedGoogle Scholar
  56. 56.
    Nelson, E. E. , Wong, L. , Uyemura, K. , Rea, T. H. , and Modlin, R. L. , Lepromin-induced suppressor cells in lepromatous leprosy, Cell. Immunol. 104:99–104 (1987).PubMedGoogle Scholar
  57. 57.
    Newell, K. W. , An epidemiologist’s view of leprosy, Bull, WHO 34:827–857 (1966).Google Scholar
  58. 58.
    Noordeen, S. K., Longterm effects of chemoprophylaxis among contacts of lepromatous cases, Lepr. India 49:504–509 (1977).PubMedGoogle Scholar
  59. 59.
    Noordeen, S. K., and Lopez-Bravo, L., The world leprosy situation, World Health Stat. Q. 39:122–128 (1986).PubMedGoogle Scholar
  60. 60.
    Noussitou, F. M. , Sansarricq, H. , and Walter, J. , Leprosy in Children, WHO, Geneva, 1976.Google Scholar
  61. 61.
    Oleinick, A. , Altered immunity and cancer risks: A review of the problem and analysis of the cancer mortality experience of leprosy patients, J. Natl. Cancer Inst. 43:775–781 (1969).PubMedGoogle Scholar
  62. 52.
    Pattyn, S. R. , Comportement de diverses espéces de mycobactéries dans la patte de souris, Ann. Inst. Pasteur 109:309–313 (1965).Google Scholar
  63. 63.
    Pattyn, S. R. , Use of the mouse footpad in studying thermoresistance of Mycobacterium leprae, Int. J. Lepr. 33:611–615 (1965).PubMedGoogle Scholar
  64. 64.
    Pedley, J. C. , The hypothesis of skin to skin transmission, Lepr. Rev. 48:295–297 (1977).PubMedGoogle Scholar
  65. 65.
    Prabhakaran, K. , Harris, E. B. , and Kirchheimer, W. F. , Survival of Mycobacterium lepraein tissues kept frozen at 80°C, Microbios Lett. 1:193–195 (1976).Google Scholar
  66. 66.
    Prabhakaran, K. , and Kirchheimer, W. F. , Use of 3,4-dihydroxyphenylalanine oxidation in the identification of Mycobacterium leprae, J. Bacteriol, 92:1267–1268 (1966).PubMedGoogle Scholar
  67. 67.
    Rasi, E. , Castellazzi, Z. , Garcia, L. , Quevedo, L. , and Convit, J. , Evaluation of “chemical isolation” in 1,168 leprosy patients’ homes, Int. J. Lepr. 43:101–105 (1975).Google Scholar
  68. 68.
    Rea, T. H. , Current concepts in the immunology of leprosy, Arch. Dermatol. 113:345–352 (1977).PubMedGoogle Scholar
  69. 69.
    Rees, R. J. W., The microbiology of leprosy, in: Leprosy(R. C. Hastings, ed.), pp. 31–52, Churchill Livingstone, Edinburgh, 1985.Google Scholar
  70. 70.
    Rees, R. J. W., and Mcdougall, A. C., Airborne infection with Mycobacterium leprae in mice, J. Med. Microbiol. 10:63–68 (1977).PubMedGoogle Scholar
  71. 71.
    Rees, R. J. W., and Meade, T. W., Comparison of modes of spread and incidence of tuberculosis and leprosy, Lancet 1:47–49 (1974).PubMedGoogle Scholar
  72. 72.
    Report of the Workshop on Microbiology of the Xi International Leprosy Congress, Int. J. Lepr. 47:291–294 (1979).Google Scholar
  73. 73.
    Ridley, D. S. , and Jopling, W. H. , A classification of leprosy for research purposes, Lepr. Rev. 33:119–128 (1962).PubMedGoogle Scholar
  74. 74.
    Rotberg, A., Bechelli, L. M. , and Keil, H. , The Mitsuda reaction in a non-leprous area, Int. J. Lepr. 18:209–220 (1950).Google Scholar
  75. 75.
    Russell, D. A., Worth, R. M., Scott, G. C., Vincin, D. R. , Jano, B. , Fasal, P. , and Shepard, C. C. , Experience with acedapsone (Dadds) in a therapeutic trial in New Guinea and the chemoprophylactic trial in Micronesia, Int. J. Lepr. 44:170–176 (1976).Google Scholar
  76. 76.
    Sansarricq, H. , Walter, J. , and Seal, K. S. , The World Health Organization in leprosy control, in: A Window on Leprosy(B. R. Chatterjee, ed.), pp. 12–22, Statesman Commercial Press, Calcutta, 1978.Google Scholar
  77. 77.
    Schauf, V. , Ryan, S. , Scollard, D. , Jonasson, O., Brown, A., Nelson, K. , Smith, T. , and Vithayasai, V., Leprosy associated with Hla-DR2 and DQw1 in the population of northern Thailand, Tissue Antigens, 26:243–247 (1985).PubMedGoogle Scholar
  78. 78.
    Seckl, M. J., Monoclonal antibodies and recombinant Dna technology: Present and future uses in leprosy and tuberculosis, Int. J. Lepr. 53:618–640 (1985).Google Scholar
  79. 79.
    Sehgal, V. M., Rege, V. L., and Singh, K. P., The age of onset of leprosy, Int. J. Lepr. 45:52–55 (1977).Google Scholar
  80. 80.
    Shepard, C. C., The experimental disease that follows the injection of human leprosy bacilli into footpads of mice, J. Exp. Med. 112:445–454 (1960).PubMedGoogle Scholar
  81. 81.
    Shepard, C. C., Stability of Mycobacterium lepraeand temperature optimum for growth, Int. J. Lepr. 33:541–547 (1965).PubMedGoogle Scholar
  82. 82.
    Shepard, C. C., Experimental chemotherapy in leprosy, then and now, Int. J. Lepr. 41:307–319 (1973).Google Scholar
  83. 83.
    Shepard, C. C., and Mcrae, D. H., Mycobacterium leprae in mice:Minimal infectious dose, relationship between staining quality and infectivity, and effect of cortisone, J. Bacteriol. 89:365–372 (1965).PubMedGoogle Scholar
  84. 84.
    Shepard, C. C., and Saitz, E. W., Lepromin and tuberculin reactivity in adults not exposed to leprosy, J. Immunol. 99:637–642 (1967).PubMedGoogle Scholar
  85. 85.
    Shepard, C. C., Walker, L. L., and Vanlandingham, R. , Heat stability of Mycobacterium lepraeimmunogenicity, Infect. Immun. 22:87–93 (1978).PubMedGoogle Scholar
  86. 86.
    Shield, M. J., Stanford, J. L., and Rook, G. A. W., The reason for the reduction of the protective efficacy of Bcg in Burma, Int. J. Lepr. 47:319–320 (1979) (abstract).Google Scholar
  87. 87.
    Skinsnes, O. K. , Matsuo, E. , Chang, P. H. C., and Andersson, B., Cultivation of Mycobacterium lepraein hyaluronic acid based medium. 1. Preliminary report, Int. J. Lepr. 43:193–203 (1975).Google Scholar
  88. 88.
    Van Eden, W., Gonzalez, N. M., De Vries, R. R., Convit, J., and Van Rood, J. J., Hla-linked control of predisposition to lepromatous leprosy, J. Infect. Dis. 151:9–14 (1985).PubMedGoogle Scholar
  89. 89.
    Wade, H. W. , and Ledowsky, V. , The leprosy epidemic at Nauru: A review with data on status since 1937, Int. J. Lepr. 20:1–29 (1952).PubMedGoogle Scholar
  90. 90.
    Waldorf, D. S., Sheagren, J. N., Trautman, J. R., and Block, J. B., Impaired delayed hypersensitivity in patients with lepromatous leprosy, Lancet 2:773–776 (1966).PubMedGoogle Scholar
  91. 91.
    Walsh, G. P. , Storrs, E. E. , Burchfield, H. P. , Cottrell, E. H., Vidrine, M. F., and Binford, C. H., Leprosy-like disease occurring naturally in armadillos, J. Reticuloendothel. Soc. 18:347–351 (1975).PubMedGoogle Scholar
  92. 92.
    Wardekar, R. V. , Chemoprophylaxis in leprosy, Lepr. India 41:240–246 (1969).Google Scholar
  93. 93.
    Waters, M. F. R., Significance of the lepromin test in tuberculin-negative volunteers permanently resident in a leprosyfree area, Int. J. Lepr. 41:563 (1973).Google Scholar
  94. 94.
    Waters, M. F. R., Rees, R. J. W., Pearson, J. M. H., Laing, A. B. G., Helmy, H. S., and Gelber, R. H., Rifampicin for lepromatous leprosy: Nine years’ experience, Br. Med. J. 1:133–136 (1978).PubMedGoogle Scholar
  95. 95.
    Waters, M. F. R., Rees, R. J. W., Laing, A. B. G., Fah, K. K., Meade, T. W. , Parikshak, N., and North, W. R. S., The rate of relapse in lepromatous leprosy following completion of 20 years of supervised sulfone therapy, Lepr. Rev. 57:101–109 (1986).PubMedGoogle Scholar
  96. 96.
    WHO Expert Committee on Leprosy, Fifth Report, WHO Tech. Rep. Ser.No. 607, WHO, Geneva, 1977.Google Scholar
  97. 97.
    WHO Study Group, Chemotherapy of Leprosy for Control Programmes, WHO Tech. Rep. Ser.No. 675, WHO, Geneva, 1982.Google Scholar
  98. 98.
    Worth, R. M., and Wong, K. O., Further notes on the incidence of leprosy in Hong Kong children living with a lepromatous parent, Int. J. Lepr. 38:745–749 (1971).Google Scholar
  99. 99.
    Young, D. B., and Buchanan, T. M., A serological test for leprosy with a glycolipid specific for Mycobacterium leprae, Science 221:1057–1059 (1983).PubMedGoogle Scholar
  100. 100.
    Young, R. A., Mehra, V. , Sweetser, D., Buchanan, T., Clark-Curtiss, J., Davis, R. W., and Bloom, B. R., Genes for the major protein antigens of the leprosy parasite Mycobacterium leprae, Nature 316:450–452 (1985).PubMedGoogle Scholar

Suggested Reading

  1. Bahong, J. , and Noordeen, S. K. , Leprosy, in: Tropical Disease Research: A Global Partnership(J. Maurice and A. M. Pearce, eds.), pp. 113–124, WHO, Geneva, 1987.Google Scholar
  2. Harboe, M. (ed.), Immunology of Leprosy: Proceedings of an International Symposium, Lepr. Rev. 57(Suppl. 2): 1–308 (1986).Google Scholar
  3. Hastings, R. C. (ed.), Leprosy, Churchill Livingstone, Edinburgh, 1985.Google Scholar
  4. WHO Study Group, Chemotherapy of Leprosy for Control Programmes, WHO Tech. Rep. Ser.No. 675, WHO, Geneva, 1982.Google Scholar
  5. World Health Organization, A Guide to Leprosy Control, Publ. No. ISBN 92–4–154147–4, Geneva, 1980.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Robert R. Jacobson
    • 1
  1. 1.Clinical BranchGillis W. Long Hansen’s Disease CenterCarvilleUSA

Personalised recommendations